Texas Children's Hospital
Houston, Texas, 77030, United States
NCT Number: NCT01483079
Human milk feeding is associated with great benefits to the health and development of infants, especially in premature infants. Some mothers are unable or unwilling to provide breast milk to their infant. The use of donor human milk products for very low birth weight infants as an alternative to cow milk has risen dramatically in the past year.
Purpose: To evaluate post-discharge growth and neurodevelopment of infants less than or equal to 1250 grams birth weight receiving an exclusive human milk protein diet.
This study is active but is not currently recruiting participants.
Notify MeAll sexes
Observational
Houston, Texas, 77030, United States
An exclusive human milk protein diet in infants less than 1250 grams birth weight has been shown to reduce the rate of necrotizing enterocolitis, a devastating intestinal disease in premature infants, by 50%. New guidelines were introduced in 2009 at Texas Children's Hospital to outline the appropriate use of donor human milk products.
First, infants from a previous study will be identified and recruited for this study. Other potential subjects (infants) will be identified by the GCRC nursing staff at Texas Childrens Hospital upon admission to the neonatal intensive care unit (NICU) (Levels 2 and 3) and communicated to the PI and PIs staff.
This study includes three visits:
If infants were not originally followed in the H-26923 study, additional data will be collected from the infants chart for the hospitalization in the NICU. Data collected will include: anthropometrics at birth and discharge, enteral feeding data and parenteral nutrition throughout admission, nutrition related labs, APGAR scores, medications- lasix, chlorothiazide, dopamine, hydrocortisone and dexamethasone, morbidities such as necrotizing enterocolitis, patent ductus arteriosus, spontaneous intestinal perforation, intraventricular hemorrhage, sepsis, and chronic lung disease.
If infants are re-hospitalized or they receive their primary care from a Texas Childrens Pediatrics Associates Clinic, with the consent of the subjects parents, we would collect information from the chart including: interim anthropometric data, interim medical history, nutrition data and history, and nutrition related labs.
No interventions are part of this protocol.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 12-15 months of age
Per the protocol procedures, growth and development will be assessed at each study visit.
Time frame: 18-22 months of age
Per the protocol procedures, growth and development will be assessed at each study visit.
Time frame: 5 years of age
Per the protocol procedures, growth and development will be assessed at each study visit.
Baylor College of Medicine
Other
Evaluation of Post-Discharge Growth and Development of Infants Who Received Donor Human Milk Products in the NICU
Acronym: NICU
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07725367
Developmental Delays, Female Urogenital Diseases and Pregnancy Complications
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT05525585
Enteral Feeding Intolerance, Female Urogenital Diseases and Pregnancy Complications
Birmingham, Alabama, United States
View Trial DetailsNCT07531134
Female Urogenital Diseases and Pregnancy Complications, Low Birth Weight
Hadera, Israel
View Trial DetailsNCT05065385
Female Urogenital Diseases and Pregnancy Complications, Obstetric Labor Complications
Zurich, Canton of Zurich, Switzerland
View Trial Details